Search
Insulin glulisine
go.drugbank.com/drugs/DB01309ApprovedInsulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. … Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersProducts: APIDRA OPTIPEN 100 IU/ML SC KULLANIMI İÇİN ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, APIDRA ®Acetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea, 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamidePegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigationalIt is used following surgical resection of the primary tumor to detect areas of remaining cancer. … Pegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the parent molecule optically inactive.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingTrifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigationalto vitamin A and are analogous only in function. … as compared to older, less selective retinoids.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: AKLIEF CREAM 50MCG/GErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. … [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]
Categories: P-glycoprotein substrates, Sodium-Glucose Transporter 2 InhibitorsSynonyms: (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranoseEptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigationalEptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).
Products: Vyepti® 100 mg/mL concentrate for solution for infusionFecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalFecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients … [A259182,L46217,L46222] Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge.
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235103,L34193] Patients with NSCLC often develop resistance to drugs that target EGFR and MET individually, so amivantamab was developed to attack both targets, reducing the chance of resistance developing … FDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with
Products: Rybrevant ScBepotastine
go.drugbank.com/drugs/DB04890ApprovedBepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.
Categories: Heterocyclic Compounds, 1-RingProducts: DOLCETTINA®Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Categories: P-glycoprotein inhibitors, Complement Factor D InhibitorSynonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide